Abstract

BackgroundCertolizumab pegol (CZP) demonstrated a fast response and acceptable safety profile in clinical studies in rheumatoid arthritis (RA).1-3ObjectivesTo assess use of CZP in daily clinical practice in Germany.MethodsThe efficacy and...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0084 Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol-treated rheumatoid arthritis patients
B Haraoui ... K Luijtens
Annals of the Rheumatic Diseases | VOL. 71
B Haraoui, et. al.B Haraoui ... K Luijtens
01 Jun 2013
THU0136 Use of A Global Risk Score To Identify Patients with Rheumatoid Arthritis at Risk of Serious Infectious Events during Certolizumab Pegol Treatment
...
Annals of the Rheumatic Diseases | VOL. 75
, et. al. ...
01 Jun 2016
SAT0164 The First Study of Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients Led to Sustained Clinical Response and Inhibition of Radiographic Progression at 52 Weeks: The C-Early Randomized, Double-Blind, Controlled Phase 3 Study
P Emery ... D Tatla
Annals of the Rheumatic Diseases | VOL. 74
P Emery, et. al.P Emery ... D Tatla
01 Jun 2015
SAT0149 Identification of Time-Dependent Risk Factors for Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
J.R Curtis ... C O'Brien
Annals of the Rheumatic Diseases | VOL. 74
J.R Curtis, et. al.J.R Curtis ... C O'Brien
01 Jun 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers